Revolutionizing Bispecific Drugs for Autoimmune & Inflammatory Diseases Treatment of Autoantibody-Driven Diseases with Bispecific T Cell Engaging IgM Antibodies

Time: 10:30 am
day: Day Two


  • Highlighting the unique potential of IgM antibodies for treatment of autoimmune disease
  • Utilizing T cells to drive deep B cell depletion for B cell mediated autoimmune diseases
  • Sharing pipeline updates including the ongoing imvotamab (CD20 x CD3) Phase 1b clinical trials